Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study

Overview of attention for article published in Frontiers in Neurology, July 2024

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (86th percentile)
High Attention Score compared to outputs of the same age and source (95th percentile)

So far, Altmetric has seen 1 news story.

Patients with type 2 or type 3 spinal muscular atrophy (SMA) experience sustained motor function benefits from apitegromab (SRK-0…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.